PCM
IMCR icon

Prelude Capital Management’s Immunocore IMCR Stock Holding History

Prelude Capital Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,507
Closed -$573K – 1390
2025
Q4 		$573K Buy
+16,507
New +$583K 0.04% 480
2023
Q3 		– Sell
-3,985
Closed -$239K – 1235
2023
Q2 		$239K Buy
+3,985
New +$227K 0.02% 759

Other funds holding IMCR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Prelude Capital Management's IMCR Position: Q1 2026 in Review

Prelude Capital Management sold out of Immunocore (IMCR) in Q1 2026, closing a stake of 16,507 shares — an estimated $573K sold.

Prelude Capital Management first reported a position in IMCR in Q2 2023 and held it in 2 quarters. The position peaked at $573K in Q4 2025. 142 funds tracked by Wall St. Rank hold IMCR as of Q1 2026.

  • Prelude Capital Management reported no remaining Immunocore position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 16,507 Immunocore shares in Q1 2026, an estimated $573K.
  • Prelude Capital Management first reported a position in Immunocore in Q2 2023 and held it in 2 quarters.
  • Prelude Capital Management's Immunocore position peaked at $573K in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Immunocore as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.